MSB 2.70% 95.0¢ mesoblast limited

Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-20

  1. 12,452 Posts.
    lightbulb Created with Sketch. 3375
    That fits nicely with the H12023 approval period

    Mesoblast has comb through and answered all the CRL questions
    Got ODAC 9-1 vote
    Got long term data as insurance

    What else does the FDA need?
    Ryoncil approval will certainly change the dynamics of this company - we are on our way to commercialisation - finally!!!
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
95.0¢
Change
0.025(2.70%)
Mkt cap ! $1.084B
Open High Low Value Volume
94.0¢ 96.8¢ 93.5¢ $4.207M 4.417M

Buyers (Bids)

No. Vol. Price($)
3 42268 94.0¢
 

Sellers (Offers)

Price($) Vol. No.
95.0¢ 48002 3
View Market Depth
Last trade - 16.10pm 09/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.